Enovis (NYSE:ENOV) Director Sharon Wienbar Buys 907 Shares of Company Stock

Enovis Corporation (NYSE:ENOV) Director Sharon Wienbar acquired 907 shares of the business’s stock in a transaction that occurred on Friday, November 6th. The shares were acquired at an average cost of $27.55 per share, with a total value of $24,987.85. Following the transaction, the director directly owned 42,853 shares in the company, valued at $1,180,600.15. The trade was a 2.16% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Enovis Stock Performance

ENOV traded down $0.29 during midday trading on Tuesday, reaching $28.25. The company’s stock had a trading volume of 1,596,570 shares, compared to its average volume of 1,879,434. The stock has a market cap of $1.63 billion, a P/E ratio of 8.44 and a beta of 1.31. The company has a fifty day simple moving average of $20.05 and a 200 day simple moving average of $23.14. The company has a current ratio of 2.15, a quick ratio of 1.08 and a debt-to-equity ratio of 0.82. Enovis Corporation has a twelve month low of $16.70 and a twelve month high of $32.41.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, November 5th. The company reported $0.88 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.11. Enovis had a positive return on equity of 13.23% and a negative net margin of 22.86%. The company had revenue of $558.73 million during the quarter, compared to analyst estimates of $557.12 million. During the same period in the previous year, the company earned $0.75 earnings per share. The company’s quarterly revenue was up 1.8% compared to the same quarter last year. Research analysts expect that Enovis Corporation will post 3.15 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ENOV. Allworth Financial LP lifted its holdings in shares of Enovis by 59.7% during the 2nd quarter. Allworth Financial LP now owns 1,744 shares of the company’s stock worth $36,000 after acquiring an additional 652 shares during the period. IFP Advisors Inc increased its stake in Enovis by 5,590.5% in the second quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock valued at $25,000 after acquiring an additional 1,174 shares during the period. Inspire Investing LLC increased its stake in Enovis by 4.9% in the third quarter. Inspire Investing LLC now owns 34,833 shares of the company’s stock valued at $636,000 after acquiring an additional 1,631 shares during the period. Amundi raised its position in Enovis by 2.3% in the first quarter. Amundi now owns 74,184 shares of the company’s stock worth $1,688,000 after purchasing an additional 1,677 shares in the last quarter. Finally, Handelsbanken Fonder AB raised its position in Enovis by 9.3% in the second quarter. Handelsbanken Fonder AB now owns 21,117 shares of the company’s stock worth $437,000 after purchasing an additional 1,800 shares in the last quarter. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ENOV has been the topic of several research reports. Needham & Company LLC boosted their price objective on shares of Enovis from $34.00 to $38.00 and gave the stock a “buy” rating in a report on Thursday, November 5th. Wells Fargo & Company upped their price objective on shares of Enovis from $33.00 to $37.00 and gave the company an “overweight” rating in a research report on Friday. BTIG Research increased their target price on shares of Enovis from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, November 5th. Weiss Ratings raised Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, November 2nd. Finally, Zacks Research raised Enovis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $38.62.

Enovis Company Profile

Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.